重组促红细胞生成素防治支气管肺发育不良的临床研究  

Treatment with recombinant erythropoietin for bronchopulmonary dysplasia

作　　者：刘丽芳[1] 许茜[1] 蔡琳[1] 李晓东[1] 何中倩[1] 陈宏洁 

机构地区：[1]广东医学院附属南山人民医院儿科,深圳南山518052

出　　处：《中国生育健康杂志》2014年第6期528-530,共3页Chinese Journal of Reproductive Health

摘　　要：目的探讨重组促红细胞生成素（rhEpo）防治支气管肺发育不良（BPD）的效果。方法选择胎龄〈32周、需机械通气（包括常频及高频）治疗的患儿103例，随机分为促红细胞生成素组（51例）和常规治疗组（52例），比较两组在生后28dBPD发生率、纠正胎龄36周时BPD严重程度、死亡率、住院时间、呼吸机治疗时间、氧疗时间和并发症的发生率。结果促红细胞生成素组和常规治疗组BPD发生率（11．8％和28．8％）、纠正胎龄36周时BPD严重程度、住院时间[（32．6±11．2）d和（44．3±9．7）d]、输血量[（28．6±12．7）ml／kg和（39．6±10．6）ml／kg]和贫血发生率（35．3％和61．5％）比较，差异均有统计学意义。结论rhEpo治疗有BPD风险的早产儿可减少BPD的发生率及减轻BPD程度，减少氧疗时间，缩短住院时间，未增加早产儿视网膜病（ROP）的发生率。Objective To examine the effect of recombinant erythropoietin （rhEpo） in the treatment of bronchial pulmonary dysplasia （BPD）. Methods 103 newborns with gestational age 〈 32 weeks and requiring mechanical ventilation （including the frequency and high frequency） were randomly divided into erythropoietin （51 cases） group or routine treatment group （52 cases）. Incidence of BPD at 28th day after birth, 36th week BPD severity adjusted for gestational age, mortality, length of hospital stay, ventilator treatment time, oxygen therapy, and incidence of complications were compared between the two groups. Results Incidence of BPD adjusted for gestational age at 36th week （ 11.8% vs. 28.8% ）, mortality （9.8% vs. 13.5% ）, length of hospital stay [ （32.6 ±11.2） d vs. （44.3 ± 9.7 ） d], blood transfusion volume [ （28.6±12.7） ml/kg vs. （39.6± 10.6） ml/kg）, and incidence of anemia （35.3% vs. 61.5% ） were statistically significant between the two groups. Conclusion Treatment with rhEpo can reduce the incidence of BPD, level of BPD, duration of oxygen use and hospitalization days, while no increase in retinopathy in preterm newborns.

关 键 词：早产儿 支气管肺发育不良 重组促红细胞生成素 预防 呼吸衰竭 

分 类 号：R459.5[医药卫生—治疗学]